The Multiple Myeloma Channel is supported with funding from Sanofi (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2026 | Initial results from a Phase Ib/II trial of purinostat mesylate plus POM and DEX in R/R myeloma
Lijuan Chen, MD, PhD, West China Hospital, Sichuan University, Chengdu, China, presents findings from a Phase Ib/II trial evaluating purinostat mesylate (PM), a highly selective HDAC inhibitor, in combination with pomalidomide and low-dose dexamethasone for relapsed/refractory (R/R) multiple myeloma (MM). Prof. Chen notes that this triplet therapy demonstrated encouraging efficacy and safety in this patient population. This interview took place during the 2026 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
